Elevar's Big Bet: A Single Drug to Fight Cancers by Gene, Not by Type

FORT LEE, NJ – June 22, 2026 – In the intricate world of oncology, progress is often measured in inches. But sometimes, a company makes a move that signals a potential leap. Elevar Therapeutics, a U.S.-based subsidiary of South Korea's HLB Co., Ltd., just took such a step, announcing the first patients have been dosed in a global Phase 2 trial for its drug, lirafugratinib. While the news of a trial launch is common, the strategy behind it is what demands attention. Elevar isn't just testing a drug; it's testing a paradigm-shifting idea: treating cancer based on its genetic fingerprint, regardless of where in the body it originates.

The trial, known as ReFocus202, is evaluating lirafugratinib in patients with a variety of solid tumors—excluding cholangiocarcinoma (CCA)—that all share a specific genetic driver: an FGFR2 fusion or rearrangement. With the first patients dosed at Samsung Medical Center in Seoul and Moffitt Cancer Center in Florida, the study marks a deliberate and ambitious push toward a “tumor-agnostic” approval, a coveted prize in modern drug development.

The Science of Specificity: Targeting FGFR2's Achilles' Heel

To grasp the significance of Elevar's strategy, one must first understand the target. Fibroblast Growth Factor Receptor 2, or FGFR2, is a protein that plays a normal role in cell growth. In some cancers, however, a genetic accident occurs—a fusion or rearrangement—that essentially hotwires the FGFR2 gene, leaving it permanently switched on. This rogue signal becomes an oncogenic driver, fueling relentless cell proliferation and tumor growth.

FGFR2 alterations are most famously associated with cholangiocarcinoma, a rare and aggressive bile duct cancer, where they appear in about 10-15% of intrahepatic cases. However, advances in genomic sequencing have revealed that this same genetic flaw appears, albeit less frequently, across a wide spectrum of solid tumors, including in the stomach, breast, and central nervous system. For these patients, treatment options are often limited to grueling chemotherapy regimens that offer modest benefit.

Lirafugratinib is a potent, selective, oral small molecule inhibitor designed to shut down this errant FGFR2 signal. Unlike broader “pan-FGFR” inhibitors that block multiple members of the FGFR family and can cause a wider range of side effects, lirafugratinib’s selectivity is a key feature. By focusing its attack solely on FGFR2, the therapy aims to maximize anti-tumor activity while minimizing off-target toxicity. This precision is the cornerstone of Elevar's approach and the hope for patients whose tumors are defined by this specific genetic vulnerability.

Beyond Cholangiocarcinoma: A Calculated Expansion

Elevar's move is a masterclass in strategic sequencing. The company is not starting from scratch. Lirafugratinib is already under priority review by the FDA for its initial indication in previously treated CCA patients with FGFR2 fusions, with a regulatory decision date set for September 27, 2026. Having already secured Orphan Drug and Fast Track designations, the company has a solid regulatory foundation.

The ReFocus202 trial is the logical, and aggressive, next step. It aims to prove that the drug’s effectiveness is tied to the FGFR2 alteration itself, not the tumor's tissue of origin. This is the essence of a tumor-agnostic therapy. Success would unlock a market far larger and more diverse than CCA alone.

“Patients with advanced solid tumors harboring FGFR2 fusions or rearrangements often have limited treatment options, particularly beyond cholangiocarcinoma,” said Dr. Richard Kim, the study's principal investigator at Moffitt Cancer Center. “This study gives us an important opportunity to better understand whether selective FGFR2 inhibition with lirafugratinib can benefit a broader group of patients.”

This addresses a critical unmet need. While the FDA has approved several FGFR inhibitors for CCA, including Incyte's Pemazyre (pemigatinib) and Taiho's Lytgobi (futibatinib), and Janssen's Balversa (erdafitinib) is approved for urothelial carcinoma, no drug is specifically approved to treat the diverse array of non-CCA solid tumors driven by FGFR2 fusions. Elevar is aiming to fill that void.

Navigating a Crowded Field: Elevar's Competitive Play

The oncology market is fiercely competitive, but Elevar’s strategy for lirafugratinib is shrewd. By pursuing a tumor-agnostic label, the company is attempting to leapfrog competitors focused on single-indication approvals. A successful outcome in ReFocus202 could position lirafugratinib as the go-to therapy for any patient with an advanced solid tumor carrying an FGFR2 fusion, a clear and powerful marketing advantage that simplifies treatment decisions for oncologists.

The global footprint of the trial—with sites across the U.S., Korea, the UK, Spain, and France—reflects the ambition and financial backing of parent company HLB Co., Ltd. It’s a significant investment, signaling confidence that the data from an earlier Phase 1/2 study, which showed meaningful antitumor activity across 13 different non-CCA tumor types, can be replicated on a larger scale.

“Elevar believes lirafugratinib has much potential as a strong anti-tumor therapy across a wider range of FGFR2 fusion or rearrangement driven tumors,” stated Dong-Gun Kim, Elevar’s chief executive officer, in the company’s announcement. This confidence is bolstered by the FDA's prior actions, which suggest the agency recognizes the drug's potential to address a serious condition.

The ReFocus202 trial is an open-label, single-arm study where the primary measure of success will be the objective response rate—essentially, the percentage of patients whose tumors shrink. Elevar plans to conduct an interim analysis using data from this trial combined with its prior dataset, ensuring a robust evaluation across at least seven different tumor types. This methodical approach is designed to generate the compelling evidence needed to convince regulators of the drug's broad utility.

As the industry watches, the immediate focus remains on the upcoming PDUFA date in September for the CCA indication. A green light from the FDA would not only provide Elevar with its first commercial product but would also serve as a powerful validation of lirafugratinib's mechanism. From there, all eyes will turn to the ReFocus202 trial, a study that could transform a promising cancer drug into a versatile weapon in the arsenal of precision oncology.